Tuesday, February 4, 2025
spot_img

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company’s results and corporate developments.

What: Stereotaxis fourth quarter and full year 2024 financial results conference call
   
When: Monday, March 3, 2025 at 8:30 a.m. ET (5:30 a.m. PT)
   
Dial In Number: To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 1983976.
   
Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
   
Call Replay: A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.


About Stereotaxis

Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
                                                        
Kimberly Peery                                                
Chief Financial Officer

314-678-6100
[email protected]

Powered by SlickText.com

Hot this week

DSV, 1150 – 2024 ANNUAL REPORT

Company Announcement No. 1150 Solid financial results in...

The Board of Directors of eQ Plc has decided on a new option program

eQ Plc Stock Exchange Release4 February 2025, at 8:30 am ...

Coloplast A/S – Interim Financial Report, Q1 2024/25

2024/25 Interim financial results, Q1 2024/25 ...

Publicis Groupe : Full Year 2024 Results

Full Year 2024 Results ...

Topics

DSV, 1150 – 2024 ANNUAL REPORT

Company Announcement No. 1150 Solid financial results in...

The Board of Directors of eQ Plc has decided on a new option program

eQ Plc Stock Exchange Release4 February 2025, at 8:30 am ...

Coloplast A/S – Interim Financial Report, Q1 2024/25

2024/25 Interim financial results, Q1 2024/25 ...

Notice of the Annual General Meeting 2025

eQ Plc Stock Exchange Release4 February 2025, at 8:15 am...

Lugman Group withdraws from purchase of “Industrial Park Fechenheim”

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRMUTTENZ, 4...
spot_img

Related Articles

Popular Categories

spot_img